Clinical trials: Breast Neoplasms, Male
Breast Cancer, Prostate Cancer
Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome
Exposure to radiation can impact immune cells that are present in the blood, such as lymphocytes. It is hypothesized that larger radiation fields and/or longer courses of radiation, result in greater decrease in immune cells.
- Trial name
- NCT03383107
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Weill Medical College of Cornell University
Breast Cancer
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
The purpose of this research project is to create images of where and how the amino acid (the building blocks of proteins)Tryptophan is processed in normal and abnormal tissue in the patient's body.
- Trial name
- NCT01302821
- Testing
- Adenovirus-p53 transduced dendritic cell vaccine, 1-methyl-D-tryptophan, Carbon C 11 alpha-methyltryptophan
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Solid Tumor, Breast Cancer
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination…
- Conditions
- Solid Tumor, Breast Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT07358806
- Testing
- OCT-598, Docetaxel
- Where
- 3 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- Oscotec Inc.
Prostate Cancer
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with…
- Trial name
- NCT02130700
- Testing
- VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Innocrin Pharmaceutical
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Gastric Cancer, Invasive Breast Cancer
CONFIRM: Magnetic Resonance Guided Radiation Therapy
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer.
- Conditions
- Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma
- Trial name
- CONFIRM (NCT04368702)
- Testing
- Viewray MRIdian® Linac
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer, Prostate Cancer
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms
- Trial name
- NCT00558272
- Testing
- AZD0530, Zoledronic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Genitourinary Syndrome of Menopause, Vaginal Atrophy
Vaginal Laser Therapy in Breast Cancer Survivors
This study evaluates the efficacy of vaginal CO2 laser therapy in breast cancer survivors with symptoms of Genitourinary Syndrome of Menopause.
- Conditions
- Genitourinary Syndrome of Menopause, Vaginal Atrophy, Breast Cancer, Dyspareunia
- Trial name
- NCT03738605
- Testing
- Microablative Fractional CO2 Laser Therapy
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.
Prostate Cancers, Breast Cancer
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings.
- Conditions
- Prostate Cancers, Breast Cancer, Head and Neck Cancer, Cancer
- Trial name
- PETRiS (NCT06970275)
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 850 people
- Sponsor
- XEOS Medical
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
Breast Cancer
Comparative Study of QL1209 and Perjeta® in Healthy Male Participants
The goal of this clinical trial is to evaluate the similarity of pharmacokinetic (PK) parameters following a single intravenous infusion of QL1209 (Perjeta® biosimilar candidate) and Perjeta® (Pertuzumab) in healthy male…
- Trial name
- NCT07861139
- Testing
- QL1209, US-Perjeta®
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Non-Small-Cell Lung Carcinoma, Malignant Melanoma
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may…
- Conditions
- Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
- Trial name
- PARADIGM (NCT05037825)
- Testing
- Checkpoint Inhibitor, Immune
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- VastBiome
Brain and Central Nervous System Tumors, Breast Cancer
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy for solid tumors or lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Extragonadal Germ Cell Tumor, Infection
- Trial name
- NCT00005590
- Testing
- levofloxacin
- Where
- United Kingdom
- Sponsor
- Cancer Research Campaign Clinical Trials Centre